Valneva SE: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Valneva SE issues FY 2014 revenue guidance
Valneva SE:Sees FY 2014 IFRS revenue of 40-45 million euros.
Latest Developments for Valneva SE
- Valneva SE confirms FY 2014 outlook guidance
- Valneva SE announces first ever marketing approval in Europe for vaccine produced in EB66 cell line
- Valneva SE announces first marketing authorization for human vaccine produced in EB66 cell line
- Valneva SE announces approval and launch in South America of second veterinary vaccine produced in EB66 cell line
Latest Key Developments in Biotechnology
- Zealand Pharma A/S maintains FY 2014 financial guidance
- BioSpecifics Technologies Corp announces positive data from Phase 2a study of CCH for treatment of Cellulite
- OncoGenex Pharmaceuticals Inc announces update on phase 3 ENSPIRIT trial evaluating Custirsen in advanced non-small cell lung cancer
- Galena Biopharma appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
- Share this
- Digg this